Search results for Raxibacumab
Raxibacumab, Abbexa, abx831143
Raxibacumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting Bacillus anthracis Anthrax Protective Antigen, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Raxibacumab Biosimilar - Research Grade, ichor.bio, ICH5807
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.